Member Info for dryland

clinical validation of test expected very shortly

oops net not com

d i r e c t o r s t a l k c om

it depends what platform you use, i am with HFX and HL and neither will allow anyone to borrow your shares to short so if you are with either of these it is a pointless exercise. If you are with someone else best to give them a call to clarify.

believe me it wont be a pleasant experience i have experienced over 20 Nasoendoscopys....

i agree with BBN https://twitter.com/BigBiteNow/status/1263001400570777601

Don't get caught up in the 'noise' on here...

The Group has agreed an exclusive distribution agreement with Medusa19 for the supply of the COVID-19 rapid test direct to consumers globally, subject to the necessary regulatory approvals. Medusa19 has been established by Richard Hughes and Mahmud Kamani, both founder shareholders of Boohoo.com and shareholders of Avacta1, to build a global consumer self-testing business. Medusa19's initial focus will be on COVID-19 home testing and it is currently investing in global e-commerce, logistics and customer support infrastructure in preparation for Avacta's COVID-19 test launch. Medusa19 will also have non-exclusive rights to supply the tests to businesses for workforce testing. The distribution agreement includes a profit-sharing arrangement.

this morning

check them out on here when they are printed they slot into the time the trade was completed giving a good idea of trades around that time https://www.sharesmagazine.co.uk/shares/share/AVCT/trades

May 19 2020, 14:15 146.902 128,250 £188,401.815 buys were at 146.50 so a premium paid....lovely jubbly we know it makes sense

filtered for being a complete and utter xxxx....fill in the word of your choice

thanks for that advice i have sold my holding on the back of it. No doubt if I lose out from this I can sue you as you will have public liability insurance for your financial advice practice.

there's lots of technical info on barchart if that's your bag...it's another useful tool imo

still going strong https://www.barchart.com/stocks/quotes/AVCT.LN/opinion

there more :-)
More from Zeus Capital note out today...

"...Clearly these are illustrative calculations but they can translate into annualised royalties of $1.1bn per annum for Europe alone.

If the test is approved in US this can potentially increase the potential annual market for AVCT by at least 50% up to $1.6bn.

We also bear in mind that AVCT’s test is likely to be one of the first to market providing potential to capture a much larger share.

Additional specialised mass testing in transport hubs, for corporate use, or large social events can easily augment the market yet further."

Picked this up from advfn so apologies if already posted i haven't trawled through todays posts:

htTps://www.*************.net/avacta-group-affimers-first-class-prospects-says-zeus-capital/

"We suggest a base case valuation of AVCT of £290m. There is clearly enormous upside from a successful rollout of SARS COV-2 tests.

Even executing a fraction of this potential in FY20 would be transformational, providing cash resource to advance its promising Therapeutics pipeline. Applying market metrics it also implies that a £ multi-billion valuation of AVCT is achievable on execution."

more likely people in the know...a lot of companies are very leaky.

No they arent RD regardless of what you may read on these boards. I know this because i spoke on the phone to the manager of the RNS section of LSE (not this site) to put this BB myth to bed and he confirmed to me that no-one has access to the contents of and RNS apart from the company and nomad of course prior to release. Also the myth that an somebody knows when a RNS 'has been lodged' is just that a myth.

you will find lots of them on the ORPH board....good luck

@johnht rather than asking people on here to give you the reasons why IP and Lombard reduced their holdings, lets face it none of us really has a clue it's just guessing, why not approach them direct.